Showing 1751-1760 of 2034 results for "".
- Pfizer, BioNTech’s COVID-19 Vaccine on Brink of Full FDA Approvalhttps://modernod.com/news/pfizer-biontechs-covid-19-vaccine-on-brink-of-full-fda-approval/2479464/According to people familiar with the matter, the FDA is expected to grant full approval to Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 as soon as Monday, The New York Times reported. The sources suggested that the agency was aiming to complete the process by August 20, but was still wo
- US Prepares for Wide Rollout of COVID-19 Boosters Next Monthhttps://modernod.com/news/us-prepares-for-wide-rollout-of-covid-19-boosters-next-month/2479458/US officials announced that health agencies in the country are preparing to widely distribute third doses of mRNA COVID-19 vaccines beginning the week of September 20, citing new data that point to waning protection over time. The move was unveiled in a statement signed by health leaders includin
- Horizon Therapeutics Partners With Olympic Gold Medalist Gail Devers to Raise Awareness of Graves’ Disease and Symptoms of Thyroid Eye Disease (TED)https://modernod.com/news/horizon-therapeutics-partners-with-olympic-goldmmedalist-gail-devers-to-raise-awareness-of-graves-disease-and-symptoms-of-thyroid-eye-disease-ted/2479357/For Graves’ Disease Awareness Month in July, Horizon Therapeutics is teaming up with track star and three-time Olympic gold medalist Gail Devers, who has been living with Graves’ disease and symptoms of Thyroid Eye Disease (TED) for more than 30 years. Horizon and Ms. Devers are collaborating wit
- Iveric Bio to Present Zimura GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyseshttps://modernod.com/news/iveric-bio-to-present-zimura-gather2-enrollment-and-retention-updates-and-new-gather1-post-hoc-analyses/2479306/Iveric bio announced that today at the company’s Virtual Symposium for Investors and Analysts, Arshad M. Khanani, MD, MA, of Sierra Eye Associates, and Chairman of the GATHER2 Steering Committee, will discuss an accelerated enrollment timeline and patient retention, including injection fidelity,
- Biogen Fails to Meet Primary or Secondary Endpoints in Phase 3 Gene Therapy Study in Choroideremiahttps://modernod.com/news/biogen-fails-to-meet-primary-or-secondary-endpoints-in-phase-3-gene-therapy-study-in-choroideremia/2479291/Biogen announced topline results from the phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia. The STAR study did not meet its primary endpoint of proportion of participants with a ≥15 letter improvement fr
- Iveric Bio to Host Investor Symposium on Dry AMDhttps://modernod.com/news/iveric-bio-to-host-investor-symposium-on-dry-amd/2479282/Iveric bio announced details for its Dry Age-Related Macular Degeneration Virtual Symposium for investors and analysts being held on Friday, June 18, 2021 from 10 am to 12 pm Eastern Time. The symposium will include presentations on the company’s Zimura (avacincaptad pegol) pivotal program in geo
- Lighthouse Guild Announces the Naming of The Dorothy Strelsin Behavioral Health Clinichttps://modernod.com/news/lighthouse-guild-announces-the-naming-of-the-dorothy-strelsin-behavioral-health-clinic/2479278/In recognition of a long-time supporter of Lighthouse Guild, the organization has announced the naming of The Dorothy Strelsin Behavioral Health Clinic. Lighthouse Guild is very grateful for the steadfast support of Dorothy Strelsin, who in her lifetime made numerous initiatives possible, includi
- Biogen’s Phase 2/3 Gene Therapy Study for XLRP Fails to Meet Primary Endpointhttps://modernod.com/news/biogens-phase-2-3-gene-therapy-study-for-xlrp-fails-to-meet-primary-endpoint/2479216/Biogen announced topline results from the phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP). The XIRIUS study did not meet its primary endpoint of demonstrating a st
- At-Home App Helps Patients Stay Engaged and Adherent to Vision Monitoring Remotelyhttps://modernod.com/news/at-home-app-helps-patients-stay-engaged-and-adherent-to-vision-monitoring-remotely/2479208/Novartis announced it has begun a US pilot program for OdySight, a clinically tested mobile application designed to help monitor vision remotely. Recent changes to public health protocols, paired with a growing patient population and existing treatment burden, have placed an emphasis on vi
- Modernizing Medicine Releases Enhanced Ophthalmic Image Management to Improve Clinical Workflowhttps://modernod.com/news/modernizing-medicine-releases-enhanced-ophthalmic-image-management-to-improve-clinical-workflow/2479198/Modernizing Medicine announced it has released the latest version of ophthalmic Image Management aimed at helping ophthalmologists save time and deliver efficiency associated with diagnostic imaging workflows. Many ophthalmologists benefit from having an all-in-one solution that bridges da